A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study To Compare Tivozanib In Combination With Nivolumab To Tivozanib In Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines Of Therapy, One Of Which Is An Immune Checkpoint Inhibitor